Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 13/20 | 0.57 |
| ▸ | CA2 | P00918 | 13/20 | 0.57 |
| ▸ | CA9 | Q16790 | 4/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21102719 | 0.83 | POLB (0.63) | POLBHTTCA1CA2CA9 | |
| SCHEMBL9796331 | 0.81 | POLB (0.68) | POLBHTTCA1CA2CA9 | |
| SCHEMBL21101771 | 0.79 | POLB (0.55) | POLBHTTCA1CA2CA9 | |
| SCHEMBL14419567 | 0.73 | CA1 (0.57) | POLBHTTCA1CA2CA9 | |
| SCHEMBL247263 | 0.71 | CA1 (0.60) | POLBHTTCA1CA2CA9 | |
| SCHEMBL1186005 | 0.71 | POLB (0.59) | POLBHTTCA1CA2CA9 | |
| SCHEMBL14419572 | 0.70 | CA1 (0.56) | POLBHTTCA1CA2CA9 | |
| SCHEMBL249088 | 0.70 | ALDH1A1 (0.63) | POLBHTTCA1CA2CA9 | |
| SCHEMBL21101762 | 0.70 | ALDH1A1 (0.55) | POLBHTTCA1CA2CA9 | |
| Acetic Acid SCHEMBL3425170 | 0.69 | POLB (0.60) | POLBHTTCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019111225-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NON‑ALCOHOLIC STEATOHEPATITIS | AVALIV THERAPEUTICS (US) | 2019-06-13 | — | — | WO | disclosed |